A series of cardiometabolic-related news items has been observed from Novo Nordisk, Zealand Pharma, FDA/OFA, Lilly, MannKind, Xeris, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Insulet, Senseonics, Akero Therapeutics, Skye Bioscience, MannKind, and Xeris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Altimmune, Scholar Rock, Xeris Biopharma, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk/Metaphore Biotechnologies, Altimmune, Xeris, MannKind, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
On the second and third day of ATTD 2024, six cardiometabolic-related news items were observed from Lilly, Regeneron, Akero, Insulet, and Xeris. Below, FENIX provides highlights and insight for the respective news items.
A series of cardiometabolic-related news items have been observed from Novo Nordisk, Lilly, Zealand, Lexicon, Senseonics, Xeris, and Bayer. Below, FENIX provides highlights and insights into the respective news items.
Four cardiometabolic-related news items have been observed: Insulet (view press release; slides), Xeris Biopharma (press release), Madrigal Pharmaceuticals (press release), and Bayer (press release; slides) reported their respective Q2 ‘23 earnings. Below, FENIX provides highlights and insights into the respective news items.
A series of diabetes-related news items have been observed: Insulet announced the full market release of its Omnipod 5 hybrid closed-loop system; Arecor is acquiring Tetris Pharma who is partnered with Xeris for UK/EU/CH Ogluo commercialization (view Xeris press release); and Sanofi/Optum have partnered to reduce the cost of insulin to uninsured patients (press release). Below, FENIX provides context and insight on the respective news items.
Two diabetes news items have been observed: Xeris announced FDA approved the sNDA for Gvoke Kit (1mg/0.2 mL single-dose vial syringe kit); and Medtronic hosted its CY Q2 ’21 (FY Q1 ’22) earnings call. Below, FENIX provides highlights and insights from the Medtronic call as well as thoughts on how Xeris’s decision to develop the Gvoke Kit was likely influenced by the channel mix.
Two cardiometabolic-related news items have been observed: Lexicon announced the presentation of additional analyses from the SOLOIST and SCORED Ph3 trials at the ESC 2021 Digital Experience; and Amarin announced the on-demand, Late Breaking Science Presentation at ESC 2021 of data from the prior MI subgroup analysis of its Vascepa/Vazkepa (icosapent ethyl) Ph3 REDUCE-IT study. Of note, the full ESC 2021 conference takes place August 27-30. Below, FENIX provides highlights and insights for the respective news items.